nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—cervical cancer	0.543	1	CbGaD
Afatinib—ABCG2—Topotecan—cervical cancer	0.183	0.735	CbGbCtD
Afatinib—ABCB1—Topotecan—cervical cancer	0.066	0.265	CbGbCtD
Afatinib—ERBB2—exocrine gland—cervical cancer	0.0052	0.0635	CbGeAlD
Afatinib—HIPK4—female reproductive system—cervical cancer	0.00245	0.0299	CbGeAlD
Afatinib—ERBB2—epithelium—cervical cancer	0.00226	0.0276	CbGeAlD
Afatinib—ERBB4—epithelium—cervical cancer	0.00226	0.0276	CbGeAlD
Afatinib—ERBB2—decidua—cervical cancer	0.00214	0.0261	CbGeAlD
Afatinib—ERBB2—renal system—cervical cancer	0.0021	0.0256	CbGeAlD
Afatinib—Mucosal inflammation—Topotecan—cervical cancer	0.00208	0.107	CcSEcCtD
Afatinib—DYRK1A—decidua—cervical cancer	0.00206	0.0251	CbGeAlD
Afatinib—ERBB2—endometrium—cervical cancer	0.00203	0.0248	CbGeAlD
Afatinib—DYRK1A—renal system—cervical cancer	0.00202	0.0247	CbGeAlD
Afatinib—EPHA6—female reproductive system—cervical cancer	0.00194	0.0237	CbGeAlD
Afatinib—EGFR—uterine cervix—cervical cancer	0.0019	0.0232	CbGeAlD
Afatinib—ERBB2—uterus—cervical cancer	0.00187	0.0228	CbGeAlD
Afatinib—PHKG2—female reproductive system—cervical cancer	0.00187	0.0228	CbGeAlD
Afatinib—PHKG2—female gonad—cervical cancer	0.0017	0.0208	CbGeAlD
Afatinib—ERBB4—female reproductive system—cervical cancer	0.00168	0.0205	CbGeAlD
Afatinib—ERBB2—female reproductive system—cervical cancer	0.00168	0.0205	CbGeAlD
Afatinib—IRAK1—uterine cervix—cervical cancer	0.00168	0.0205	CbGeAlD
Afatinib—Vandetanib—EGFR—cervical cancer	0.00168	0.513	CrCbGaD
Afatinib—EGFR—mammalian vulva—cervical cancer	0.00166	0.0203	CbGeAlD
Afatinib—LCK—uterine cervix—cervical cancer	0.00164	0.02	CbGeAlD
Afatinib—Interstitial lung disease—Topotecan—cervical cancer	0.00163	0.0837	CcSEcCtD
Afatinib—DYRK1A—female reproductive system—cervical cancer	0.00162	0.0197	CbGeAlD
Afatinib—IRAK1—decidua—cervical cancer	0.0016	0.0195	CbGeAlD
Afatinib—Gefitinib—EGFR—cervical cancer	0.00159	0.487	CrCbGaD
Afatinib—EGFR—uterus—cervical cancer	0.00159	0.0193	CbGeAlD
Afatinib—LCK—decidua—cervical cancer	0.00156	0.019	CbGeAlD
Afatinib—ERBB2—female gonad—cervical cancer	0.00153	0.0187	CbGeAlD
Afatinib—ERBB4—vagina—cervical cancer	0.00152	0.0186	CbGeAlD
Afatinib—DYRK1A—female gonad—cervical cancer	0.00147	0.018	CbGeAlD
Afatinib—IRAK1—mammalian vulva—cervical cancer	0.00147	0.0179	CbGeAlD
Afatinib—BLK—lymph node—cervical cancer	0.00143	0.0175	CbGeAlD
Afatinib—LCK—mammalian vulva—cervical cancer	0.00143	0.0175	CbGeAlD
Afatinib—LCK—uterus—cervical cancer	0.00136	0.0166	CbGeAlD
Afatinib—EGFR—female gonad—cervical cancer	0.0013	0.0158	CbGeAlD
Afatinib—IRAK1—female reproductive system—cervical cancer	0.00126	0.0153	CbGeAlD
Afatinib—IRAK1—female gonad—cervical cancer	0.00114	0.014	CbGeAlD
Afatinib—LCK—female gonad—cervical cancer	0.00112	0.0136	CbGeAlD
Afatinib—LCK—vagina—cervical cancer	0.00111	0.0135	CbGeAlD
Afatinib—PHKG2—lymph node—cervical cancer	0.00109	0.0133	CbGeAlD
Afatinib—Sepsis—Topotecan—cervical cancer	0.001	0.0514	CcSEcCtD
Afatinib—ERBB2—lymph node—cervical cancer	0.000983	0.012	CbGeAlD
Afatinib—DYRK1A—lymph node—cervical cancer	0.000947	0.0116	CbGeAlD
Afatinib—ABL1—uterine cervix—cervical cancer	0.00094	0.0115	CbGeAlD
Afatinib—ABL1—decidua—cervical cancer	0.000896	0.0109	CbGeAlD
Afatinib—ABL1—renal system—cervical cancer	0.00088	0.0107	CbGeAlD
Afatinib—ABL1—endometrium—cervical cancer	0.00085	0.0104	CbGeAlD
Afatinib—EGFR—lymph node—cervical cancer	0.000834	0.0102	CbGeAlD
Afatinib—ABL1—mammalian vulva—cervical cancer	0.000823	0.01	CbGeAlD
Afatinib—ABL1—uterus—cervical cancer	0.000784	0.00956	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000754	0.0387	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000738	0.0379	CcSEcCtD
Afatinib—IRAK1—lymph node—cervical cancer	0.000736	0.00898	CbGeAlD
Afatinib—LCK—lymph node—cervical cancer	0.000717	0.00875	CbGeAlD
Afatinib—ABL1—female reproductive system—cervical cancer	0.000704	0.00859	CbGeAlD
Afatinib—Pneumonia—Topotecan—cervical cancer	0.000649	0.0333	CcSEcCtD
Afatinib—Infestation NOS—Topotecan—cervical cancer	0.000645	0.0331	CcSEcCtD
Afatinib—Infestation—Topotecan—cervical cancer	0.000645	0.0331	CcSEcCtD
Afatinib—ABL1—female gonad—cervical cancer	0.000641	0.00782	CbGeAlD
Afatinib—ABL1—vagina—cervical cancer	0.000637	0.00777	CbGeAlD
Afatinib—Stomatitis—Topotecan—cervical cancer	0.000629	0.0323	CcSEcCtD
Afatinib—Hepatobiliary disease—Topotecan—cervical cancer	0.00061	0.0313	CcSEcCtD
Afatinib—Epistaxis—Topotecan—cervical cancer	0.000608	0.0312	CcSEcCtD
Afatinib—ABCG2—uterine cervix—cervical cancer	0.000593	0.00723	CbGeAlD
Afatinib—ABCG2—decidua—cervical cancer	0.000565	0.00689	CbGeAlD
Afatinib—ABCG2—endometrium—cervical cancer	0.000536	0.00654	CbGeAlD
Afatinib—Mediastinal disorder—Topotecan—cervical cancer	0.000522	0.0268	CcSEcCtD
Afatinib—ABCG2—mammalian vulva—cervical cancer	0.000519	0.00633	CbGeAlD
Afatinib—Alopecia—Topotecan—cervical cancer	0.000512	0.0263	CcSEcCtD
Afatinib—Malnutrition—Topotecan—cervical cancer	0.000504	0.0259	CcSEcCtD
Afatinib—ABCG2—uterus—cervical cancer	0.000494	0.00603	CbGeAlD
Afatinib—Back pain—Topotecan—cervical cancer	0.000488	0.025	CcSEcCtD
Afatinib—Muscle spasms—Topotecan—cervical cancer	0.000485	0.0249	CcSEcCtD
Afatinib—Cough—Topotecan—cervical cancer	0.00044	0.0226	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000426	0.0219	CcSEcCtD
Afatinib—ABL1—lymph node—cervical cancer	0.000412	0.00503	CbGeAlD
Afatinib—Infection—Topotecan—cervical cancer	0.000409	0.021	CcSEcCtD
Afatinib—ABCG2—female gonad—cervical cancer	0.000404	0.00493	CbGeAlD
Afatinib—Nervous system disorder—Topotecan—cervical cancer	0.000403	0.0207	CcSEcCtD
Afatinib—ABCG2—vagina—cervical cancer	0.000402	0.0049	CbGeAlD
Afatinib—Skin disorder—Topotecan—cervical cancer	0.0004	0.0205	CcSEcCtD
Afatinib—Dyspnoea—Topotecan—cervical cancer	0.000367	0.0188	CcSEcCtD
Afatinib—Dyspepsia—Topotecan—cervical cancer	0.000362	0.0186	CcSEcCtD
Afatinib—Decreased appetite—Topotecan—cervical cancer	0.000358	0.0184	CcSEcCtD
Afatinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000355	0.0182	CcSEcCtD
Afatinib—Fatigue—Topotecan—cervical cancer	0.000355	0.0182	CcSEcCtD
Afatinib—Constipation—Topotecan—cervical cancer	0.000352	0.0181	CcSEcCtD
Afatinib—Body temperature increased—Topotecan—cervical cancer	0.000325	0.0167	CcSEcCtD
Afatinib—Asthenia—Topotecan—cervical cancer	0.000295	0.0152	CcSEcCtD
Afatinib—ABCB1—epithelium—cervical cancer	0.000295	0.0036	CbGeAlD
Afatinib—ABCB1—uterine cervix—cervical cancer	0.000292	0.00357	CbGeAlD
Afatinib—Pruritus—Topotecan—cervical cancer	0.000291	0.0149	CcSEcCtD
Afatinib—Diarrhoea—Topotecan—cervical cancer	0.000281	0.0145	CcSEcCtD
Afatinib—ABCB1—decidua—cervical cancer	0.000279	0.0034	CbGeAlD
Afatinib—ABCB1—renal system—cervical cancer	0.000273	0.00334	CbGeAlD
Afatinib—Dizziness—Topotecan—cervical cancer	0.000272	0.014	CcSEcCtD
Afatinib—ABCB1—endometrium—cervical cancer	0.000264	0.00323	CbGeAlD
Afatinib—Vomiting—Topotecan—cervical cancer	0.000262	0.0134	CcSEcCtD
Afatinib—ABCG2—lymph node—cervical cancer	0.00026	0.00317	CbGeAlD
Afatinib—Rash—Topotecan—cervical cancer	0.000259	0.0133	CcSEcCtD
Afatinib—Dermatitis—Topotecan—cervical cancer	0.000259	0.0133	CcSEcCtD
Afatinib—Headache—Topotecan—cervical cancer	0.000258	0.0132	CcSEcCtD
Afatinib—ABCB1—mammalian vulva—cervical cancer	0.000256	0.00312	CbGeAlD
Afatinib—Nausea—Topotecan—cervical cancer	0.000244	0.0125	CcSEcCtD
Afatinib—ABCB1—uterus—cervical cancer	0.000244	0.00297	CbGeAlD
Afatinib—ABCB1—female reproductive system—cervical cancer	0.000219	0.00267	CbGeAlD
Afatinib—ABCB1—female gonad—cervical cancer	0.000199	0.00243	CbGeAlD
Afatinib—ABCB1—vagina—cervical cancer	0.000198	0.00242	CbGeAlD
Afatinib—ABCB1—lymph node—cervical cancer	0.000128	0.00156	CbGeAlD
Afatinib—LCK—Signaling by FGFR—EGFR—cervical cancer	4.03e-05	0.00039	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—EGFR—cervical cancer	4.01e-05	0.000388	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—EGFR—cervical cancer	3.99e-05	0.000386	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—EGFR—cervical cancer	3.97e-05	0.000384	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—CTNNB1—cervical cancer	3.96e-05	0.000382	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—cervical cancer	3.95e-05	0.000382	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	3.94e-05	0.00038	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CASP8—cervical cancer	3.92e-05	0.000379	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—STAT3—cervical cancer	3.9e-05	0.000377	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CTNNB1—cervical cancer	3.9e-05	0.000376	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-DQB1—cervical cancer	3.85e-05	0.000372	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NOTCH1—cervical cancer	3.81e-05	0.000369	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	3.8e-05	0.000367	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—MTOR—cervical cancer	3.78e-05	0.000365	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—EGFR—cervical cancer	3.76e-05	0.000363	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	3.76e-05	0.000363	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—EGFR—cervical cancer	3.76e-05	0.000363	CbGpPWpGaD
Afatinib—PHKG2—Disease—STAT3—cervical cancer	3.74e-05	0.000361	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—WNT5A—cervical cancer	3.73e-05	0.000361	CbGpPWpGaD
Afatinib—ERBB2—Disease—MTHFR—cervical cancer	3.73e-05	0.00036	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—EGFR—cervical cancer	3.72e-05	0.00036	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—cervical cancer	3.72e-05	0.000359	CbGpPWpGaD
Afatinib—ERBB2—Disease—TERT—cervical cancer	3.72e-05	0.000359	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-DQB1—cervical cancer	3.71e-05	0.000359	CbGpPWpGaD
Afatinib—ERBB2—Immune System—FGFR3—cervical cancer	3.69e-05	0.000357	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—EGFR—cervical cancer	3.69e-05	0.000357	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—EGFR—cervical cancer	3.67e-05	0.000355	CbGpPWpGaD
Afatinib—ERBB4—Disease—MTHFR—cervical cancer	3.67e-05	0.000355	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	3.66e-05	0.000354	CbGpPWpGaD
Afatinib—ERBB4—Disease—TERT—cervical cancer	3.66e-05	0.000354	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—MTOR—cervical cancer	3.64e-05	0.000352	CbGpPWpGaD
Afatinib—ERBB4—Immune System—FGFR3—cervical cancer	3.64e-05	0.000352	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOTCH2—cervical cancer	3.62e-05	0.00035	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	3.6e-05	0.000348	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD8A—cervical cancer	3.6e-05	0.000348	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—FGFR3—cervical cancer	3.59e-05	0.000347	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOTCH2—cervical cancer	3.57e-05	0.000345	CbGpPWpGaD
Afatinib—EGFR—Disease—WNT5A—cervical cancer	3.56e-05	0.000344	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—EGFR—cervical cancer	3.55e-05	0.000343	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DPB1—cervical cancer	3.5e-05	0.000339	CbGpPWpGaD
Afatinib—BLK—Immune System—FGFR3—cervical cancer	3.5e-05	0.000338	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-DQB1—cervical cancer	3.5e-05	0.000338	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—CASP3—cervical cancer	3.48e-05	0.000336	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—EGFR—cervical cancer	3.48e-05	0.000336	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CA9—cervical cancer	3.47e-05	0.000335	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD8A—cervical cancer	3.47e-05	0.000335	CbGpPWpGaD
Afatinib—LCK—Disease—WNT5A—cervical cancer	3.43e-05	0.000332	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—cervical cancer	3.41e-05	0.00033	CbGpPWpGaD
Afatinib—ERBB2—Disease—FGFR3—cervical cancer	3.41e-05	0.00033	CbGpPWpGaD
Afatinib—PHKG2—Disease—EGFR—cervical cancer	3.4e-05	0.000328	CbGpPWpGaD
Afatinib—ERBB4—Disease—FGFR3—cervical cancer	3.36e-05	0.000325	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—CASP3—cervical cancer	3.35e-05	0.000324	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	3.33e-05	0.000322	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—WNT2—cervical cancer	3.29e-05	0.000318	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD8A—cervical cancer	3.27e-05	0.000315	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NOTCH1—cervical cancer	3.26e-05	0.000315	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—MTOR—cervical cancer	3.23e-05	0.000312	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CD4—cervical cancer	3.22e-05	0.000311	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	3.2e-05	0.00031	CbGpPWpGaD
Afatinib—ERBB2—Disease—NOTCH1—cervical cancer	3.2e-05	0.000309	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—WNT2—cervical cancer	3.17e-05	0.000307	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CASP8—cervical cancer	3.16e-05	0.000305	CbGpPWpGaD
Afatinib—ERBB4—Disease—NOTCH1—cervical cancer	3.15e-05	0.000305	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—EGFR—cervical cancer	3.13e-05	0.000303	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CASP8—cervical cancer	3.11e-05	0.000301	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—EGFR—cervical cancer	3.09e-05	0.000298	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	3.08e-05	0.000298	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CASP8—cervical cancer	3.07e-05	0.000296	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FGFR3—cervical cancer	3.07e-05	0.000296	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—EGFR—cervical cancer	3.01e-05	0.000291	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DPB1—cervical cancer	3e-05	0.000289	CbGpPWpGaD
Afatinib—BLK—Immune System—CASP8—cervical cancer	2.99e-05	0.000289	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HES1—cervical cancer	2.97e-05	0.000287	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—EGFR—cervical cancer	2.96e-05	0.000286	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FGFR3—cervical cancer	2.95e-05	0.000285	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FGFR3—cervical cancer	2.94e-05	0.000284	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HES1—cervical cancer	2.93e-05	0.000283	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—STAT3—cervical cancer	2.92e-05	0.000282	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKAP13—cervical cancer	2.89e-05	0.000279	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DPB1—cervical cancer	2.89e-05	0.000279	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—STAT3—cervical cancer	2.86e-05	0.000277	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CTNNB1—cervical cancer	2.86e-05	0.000276	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—EGFR—cervical cancer	2.85e-05	0.000276	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FGFR3—cervical cancer	2.84e-05	0.000274	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—STAT3—cervical cancer	2.82e-05	0.000272	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—EGFR—cervical cancer	2.81e-05	0.000272	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKAP13—cervical cancer	2.79e-05	0.000269	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DQB1—cervical cancer	2.74e-05	0.000264	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FGFR3—cervical cancer	2.67e-05	0.000258	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CASP8—cervical cancer	2.62e-05	0.000253	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOTCH2—cervical cancer	2.62e-05	0.000253	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TERT—cervical cancer	2.6e-05	0.000251	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MTOR—cervical cancer	2.6e-05	0.000251	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD4—cervical cancer	2.59e-05	0.000251	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TERT—cervical cancer	2.56e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—EGFR—cervical cancer	2.56e-05	0.000247	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MTOR—cervical cancer	2.56e-05	0.000247	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD8A—cervical cancer	2.56e-05	0.000247	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD4—cervical cancer	2.56e-05	0.000247	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—CTNNB1—cervical cancer	2.53e-05	0.000245	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CASP8—cervical cancer	2.53e-05	0.000244	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MTOR—cervical cancer	2.52e-05	0.000244	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD4—cervical cancer	2.52e-05	0.000243	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—WNT5A—cervical cancer	2.5e-05	0.000241	CbGpPWpGaD
Afatinib—BLK—Immune System—MTOR—cervical cancer	2.46e-05	0.000238	CbGpPWpGaD
Afatinib—BLK—Immune System—CD4—cervical cancer	2.46e-05	0.000237	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.42e-05	0.000234	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—WNT5A—cervical cancer	2.4e-05	0.000232	CbGpPWpGaD
Afatinib—ERBB2—Disease—MTOR—cervical cancer	2.4e-05	0.000232	CbGpPWpGaD
Afatinib—ERBB2—Disease—CD4—cervical cancer	2.39e-05	0.000231	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FGFR3—cervical cancer	2.39e-05	0.000231	CbGpPWpGaD
Afatinib—ERBB4—Disease—MTOR—cervical cancer	2.36e-05	0.000228	CbGpPWpGaD
Afatinib—ERBB4—Disease—CD4—cervical cancer	2.36e-05	0.000228	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FGFR3—cervical cancer	2.35e-05	0.000227	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DQB1—cervical cancer	2.34e-05	0.000226	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.34e-05	0.000226	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CTNNB1—cervical cancer	2.3e-05	0.000223	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CASP8—cervical cancer	2.28e-05	0.000221	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CTNNB1—cervical cancer	2.27e-05	0.000219	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—cervical cancer	2.27e-05	0.000219	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DQB1—cervical cancer	2.25e-05	0.000218	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOTCH1—cervical cancer	2.24e-05	0.000217	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CTNNB1—cervical cancer	2.24e-05	0.000216	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—STAT3—cervical cancer	2.21e-05	0.000213	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOTCH1—cervical cancer	2.21e-05	0.000213	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD8A—cervical cancer	2.18e-05	0.000211	CbGpPWpGaD
Afatinib—BLK—Immune System—CTNNB1—cervical cancer	2.18e-05	0.000211	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—CTNNB1—cervical cancer	2.17e-05	0.000209	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MTOR—cervical cancer	2.16e-05	0.000208	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD4—cervical cancer	2.15e-05	0.000208	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HES1—cervical cancer	2.15e-05	0.000207	CbGpPWpGaD
Afatinib—ERBB2—Disease—CTNNB1—cervical cancer	2.13e-05	0.000206	CbGpPWpGaD
Afatinib—LCK—Immune System—CD8A—cervical cancer	2.1e-05	0.000203	CbGpPWpGaD
Afatinib—ERBB4—Disease—CTNNB1—cervical cancer	2.1e-05	0.000202	CbGpPWpGaD
Afatinib—ABL1—Immune System—FGFR3—cervical cancer	2.09e-05	0.000202	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MTOR—cervical cancer	2.08e-05	0.000201	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD4—cervical cancer	2.07e-05	0.0002	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—MTOR—cervical cancer	2.07e-05	0.0002	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD4—cervical cancer	2.07e-05	0.0002	CbGpPWpGaD
Afatinib—EGFR—Disease—HES1—cervical cancer	2.05e-05	0.000198	CbGpPWpGaD
Afatinib—ERBB2—Immune System—STAT3—cervical cancer	2.01e-05	0.000194	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—cervical cancer	2.01e-05	0.000194	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—MTOR—cervical cancer	2e-05	0.000193	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD4—cervical cancer	1.99e-05	0.000193	CbGpPWpGaD
Afatinib—ERBB4—Immune System—STAT3—cervical cancer	1.98e-05	0.000191	CbGpPWpGaD
Afatinib—LCK—Disease—HES1—cervical cancer	1.98e-05	0.000191	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CTNNB1—cervical cancer	1.91e-05	0.000185	CbGpPWpGaD
Afatinib—BLK—Immune System—STAT3—cervical cancer	1.9e-05	0.000184	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—STAT3—cervical cancer	1.89e-05	0.000182	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TERT—cervical cancer	1.88e-05	0.000182	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MTOR—cervical cancer	1.88e-05	0.000182	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CA9—cervical cancer	1.88e-05	0.000181	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—cervical cancer	1.88e-05	0.000181	CbGpPWpGaD
Afatinib—ERBB2—Disease—STAT3—cervical cancer	1.85e-05	0.000179	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.85e-05	0.000179	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CTNNB1—cervical cancer	1.84e-05	0.000178	CbGpPWpGaD
Afatinib—ERBB4—Disease—STAT3—cervical cancer	1.83e-05	0.000176	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—cervical cancer	1.83e-05	0.000176	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—cervical cancer	1.8e-05	0.000174	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—cervical cancer	1.8e-05	0.000174	CbGpPWpGaD
Afatinib—EGFR—Disease—TERT—cervical cancer	1.8e-05	0.000174	CbGpPWpGaD
Afatinib—ABL1—Immune System—CASP8—cervical cancer	1.79e-05	0.000173	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGFR3—cervical cancer	1.79e-05	0.000173	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—cervical cancer	1.77e-05	0.000171	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH2—cervical cancer	1.75e-05	0.000169	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—cervical cancer	1.74e-05	0.000168	CbGpPWpGaD
Afatinib—LCK—Disease—TERT—cervical cancer	1.73e-05	0.000167	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—cervical cancer	1.73e-05	0.000167	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGFR3—cervical cancer	1.73e-05	0.000167	CbGpPWpGaD
Afatinib—LCK—Immune System—FGFR3—cervical cancer	1.72e-05	0.000166	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH2—cervical cancer	1.69e-05	0.000163	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—cervical cancer	1.69e-05	0.000163	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MTOR—cervical cancer	1.68e-05	0.000162	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CTNNB1—cervical cancer	1.67e-05	0.000161	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—cervical cancer	1.66e-05	0.00016	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MTOR—cervical cancer	1.65e-05	0.00016	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—cervical cancer	1.65e-05	0.00016	CbGpPWpGaD
Afatinib—EGFR—Disease—FGFR3—cervical cancer	1.65e-05	0.000159	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOTCH1—cervical cancer	1.62e-05	0.000157	CbGpPWpGaD
Afatinib—LCK—Disease—FGFR3—cervical cancer	1.59e-05	0.000154	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.55e-05	0.00015	CbGpPWpGaD
Afatinib—EGFR—Disease—NOTCH1—cervical cancer	1.55e-05	0.00015	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CASP3—cervical cancer	1.55e-05	0.000149	CbGpPWpGaD
Afatinib—EGFR—Immune System—CASP8—cervical cancer	1.53e-05	0.000148	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CASP3—cervical cancer	1.52e-05	0.000147	CbGpPWpGaD
Afatinib—LCK—Disease—NOTCH1—cervical cancer	1.49e-05	0.000144	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CTNNB1—cervical cancer	1.49e-05	0.000144	CbGpPWpGaD
Afatinib—LCK—Immune System—CASP8—cervical cancer	1.47e-05	0.000142	CbGpPWpGaD
Afatinib—ABL1—Immune System—MTOR—cervical cancer	1.47e-05	0.000142	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—cervical cancer	1.47e-05	0.000142	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CTNNB1—cervical cancer	1.47e-05	0.000142	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—cervical cancer	1.46e-05	0.000141	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—cervical cancer	1.45e-05	0.00014	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HES1—cervical cancer	1.44e-05	0.000139	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—cervical cancer	1.41e-05	0.000136	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—cervical cancer	1.4e-05	0.000135	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HES1—cervical cancer	1.38e-05	0.000134	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—cervical cancer	1.36e-05	0.000132	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—cervical cancer	1.32e-05	0.000128	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—cervical cancer	1.3e-05	0.000126	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—cervical cancer	1.3e-05	0.000125	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—cervical cancer	1.28e-05	0.000124	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—cervical cancer	1.26e-05	0.000122	CbGpPWpGaD
Afatinib—EGFR—Immune System—MTOR—cervical cancer	1.26e-05	0.000121	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—cervical cancer	1.25e-05	0.000121	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MTOR—cervical cancer	1.21e-05	0.000117	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—cervical cancer	1.21e-05	0.000117	CbGpPWpGaD
Afatinib—LCK—Immune System—MTOR—cervical cancer	1.21e-05	0.000117	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—cervical cancer	1.21e-05	0.000117	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—cervical cancer	1.18e-05	0.000114	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—cervical cancer	1.16e-05	0.000112	CbGpPWpGaD
Afatinib—EGFR—Disease—MTOR—cervical cancer	1.16e-05	0.000112	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—cervical cancer	1.16e-05	0.000112	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR3—cervical cancer	1.15e-05	0.000112	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—cervical cancer	1.14e-05	0.00011	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—cervical cancer	1.12e-05	0.000108	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—cervical cancer	1.12e-05	0.000108	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—cervical cancer	1.12e-05	0.000108	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—cervical cancer	1.11e-05	0.000108	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR3—cervical cancer	1.11e-05	0.000108	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—cervical cancer	1.08e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—cervical cancer	1.08e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—cervical cancer	1.07e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—cervical cancer	1.04e-05	0.000101	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—cervical cancer	1.03e-05	9.98e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—cervical cancer	1.03e-05	9.94e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—cervical cancer	9.91e-06	9.58e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—cervical cancer	9.91e-06	9.57e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—cervical cancer	9.76e-06	9.43e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—cervical cancer	9.71e-06	9.38e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—cervical cancer	9.39e-06	9.07e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—cervical cancer	9.36e-06	9.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—cervical cancer	8.96e-06	8.66e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—cervical cancer	8.64e-06	8.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—cervical cancer	8.53e-06	8.24e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—cervical cancer	8.5e-06	8.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—cervical cancer	8.12e-06	7.85e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—cervical cancer	7.85e-06	7.59e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—cervical cancer	7.83e-06	7.56e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—cervical cancer	7.62e-06	7.36e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—cervical cancer	7.47e-06	7.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—cervical cancer	7.2e-06	6.96e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—cervical cancer	7.2e-06	6.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—cervical cancer	7.16e-06	6.92e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—cervical cancer	6.94e-06	6.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—cervical cancer	6.28e-06	6.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—cervical cancer	6.05e-06	5.84e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—cervical cancer	5.5e-06	5.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—cervical cancer	4.79e-06	4.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—cervical cancer	4.62e-06	4.46e-05	CbGpPWpGaD
